Peptide-Based Radiopharmaceuticals

Peptide-based radiopharmaceuticals use peptides to deliver radioactive isotopes directly to specific cells, primarily for cancer imaging and treatment. These peptides are engineered to target receptors that are overexpressed on cancer cells, which helps to minimize harm to healthy tissue. A typical peptide-based radiopharmaceutical is composed of a peptide ligand, a linker, a chelating agent, and a radioactive isotope. They offer several advantages, including high specificity, improved imaging quality, and therapeutic effectiveness.

Our group is focused on developing novel peptide-based radiopharmaceuticals that target overexpressed cancer biomarkers on cancer cells. To achieve this, we employ a high-throughput screening method utilizing a combinatorial peptide library. To enhance the binding affinity and specificity of the peptide ligand, we incorporate a small molecule ligand into the peptide library.

Once promising candidates are identified, we use AI and structure-based design tools to optimize their properties. This computational approach allows us to refine the peptides for better performance before moving to the next phase of development. Finally, we conduct in vitro and in vivo validations to select the most suitable candidate for further preclinical and clinical trials. This comprehensive approach, which integrates high-throughput screening, computational design, and rigorous validation, aims to accelerate the development of effective and safe peptide-based radiopharmaceuticals for personalized cancer care.